- Home
- JMM vs QNCX Comparison
JMM vs QNCX Comparison
Compare JMM & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- QNCX
- Stock Information
- Founded
- JMM 1988
- QNCX 2012
- Country
- JMM United States
- QNCX United States
- Employees
- JMM N/A
- QNCX N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JMM Finance
- QNCX Health Care
- Exchange
- JMM Nasdaq
- QNCX Nasdaq
- Market Cap
- JMM 58.5M
- QNCX 47.7M
- IPO Year
- JMM N/A
- QNCX 2019
- Fundamental
- Price
- JMM $6.19
- QNCX $1.31
- Analyst Decision
- JMM
- QNCX Strong Buy
- Analyst Count
- JMM 0
- QNCX 5
- Target Price
- JMM N/A
- QNCX $8.00
- AVG Volume (30 Days)
- JMM 16.1K
- QNCX 304.4K
- Earning Date
- JMM 01-01-0001
- QNCX 08-12-2025
- Dividend Yield
- JMM 5.44%
- QNCX N/A
- EPS Growth
- JMM N/A
- QNCX N/A
- EPS
- JMM N/A
- QNCX N/A
- Revenue
- JMM N/A
- QNCX N/A
- Revenue This Year
- JMM N/A
- QNCX N/A
- Revenue Next Year
- JMM N/A
- QNCX N/A
- P/E Ratio
- JMM N/A
- QNCX N/A
- Revenue Growth
- JMM N/A
- QNCX N/A
- 52 Week Low
- JMM $5.29
- QNCX $0.51
- 52 Week High
- JMM $6.10
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- JMM 50.23
- QNCX 64.64
- Support Level
- JMM $6.06
- QNCX $1.29
- Resistance Level
- JMM $6.27
- QNCX $1.45
- Average True Range (ATR)
- JMM 0.09
- QNCX 0.09
- MACD
- JMM -0.01
- QNCX 0.03
- Stochastic Oscillator
- JMM 54.55
- QNCX 76.74
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.